Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448760 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00448760 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 29 participants.
The verdict
NCT00448760, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, floxuridine, docetaxel, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with previously untreated stage II or stage III esophageal cancer that can be removed by surgery.
Interventions
- DRUG Docetaxel
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Floxuridine
- GENETIC Microarray analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2004-10 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00448760
The ClinicalTrials.gov registry entry for NCT00448760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT00448760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00448760 about?
NCT00448760 is a clinical study titled "Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery". RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, floxuridine, docetaxel, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells....
What is the current status of trial NCT00448760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2004-10. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00448760?
The interventions under investigation include: Docetaxel (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), Floxuridine (DRUG), Microarray analysis (GENETIC).
Who is sponsoring clinical trial NCT00448760?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.